The Ongoing Quest for Female Sexual Wellness: Beyond the “Pink Pill” For decades, pharmaceutical solutions for male sexual dysfunction, like Viagra and Cialis, have been readily available. Yet, a comparable option for women has been a more elusive goal. Now, a new documentary, “The Pink Pill: Sex, Drugs & Who Has Control,” premiering on Paramount+, … Read more
Lilly’s New Playbook: Expanding Access to Obesity Drugs and Reshaping the Market Eli Lilly has launched “Employer Connect,” a new platform aimed at making its obesity drug, Zepbound, more accessible to employees through their health insurance. This move addresses a significant hurdle in the rapidly evolving obesity treatment landscape: cost and inconsistent employer coverage. Although … Read more
Gene Editing and the Future of Pancreas Transplants: A Fresh Hope for Type 1 Diabetes Four weeks after transplanting genetically modified insulin-producing cells into a patient with type 1 diabetes, researchers at Uppsala University Hospital achieved a breakthrough: the transplanted cells were alive and functioning, despite the patient not taking any immune-system-suppressive drugs. This marks … Read more
Breast Cancer Cases Projected to Surge Globally: A Looming Health Crisis Despite advancements in treatment, a new analysis from the Global Burden of Disease Study Breast Cancer Collaborators paints a concerning picture: global breast cancer cases are predicted to increase by a third, rising from 2.3 million in 2023 to over 3.5 million in 2050. … Read more
Trump’s Drug Pricing Deals: A Three-Year Window for Change? President Trump’s push for lower prescription drug prices, often touted through “most-favored nation” (MFN) deals with pharmaceutical companies, continues to be a subject of scrutiny. Recent Securities and Exchange Commission (SEC) filings reveal a key detail previously undisclosed: at least some of these agreements are set … Read more
Novartis Settlement Marks a Turning Point in Biomedical Ethics In a landmark decision finalized this month, Novartis has settled a lawsuit brought by the estate of Henrietta Lacks. The suit alleged the pharmaceutical giant unjustly profited from HeLa cells – cells taken from Lacks’ tumor without her knowledge in 1951. While the details of the … Read more
Denmark’s Economic Puzzle: Why Consumer Gloom Persists Despite Strong Numbers Denmark presents a fascinating economic paradox. Despite record-high house prices and near-zero unemployment, consumer sentiment remains surprisingly subdued. According to Helge Pedersen, chief economist at Nordea Bank, ordinary Danes are still deeply concerned about inflation, even as the official rate has fallen to 0.8%. The … Read more
Minnesota’s 340B Drug Pricing Program: A Glimpse into the Future of Drug Discounts A recent report from the Minnesota Department of Health reveals that hospitals and clinics participating in the 340B Drug Pricing Program generated at least $1.34 billion in revenue in 2024. The program, a federal initiative allowing eligible healthcare providers to purchase discounted … Read more
Inovio Pharmaceuticals Investors Face Deadline in Securities Fraud Lawsuit Investors who purchased Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023, and December 26, 2025, may be eligible to join a class action lawsuit. A lead plaintiff deadline of April 7, 2026, has been set, according to Rosen Law Firm, a global investor rights … Read more
DOJ Backs AbbVie in 340B Drug Pricing Dispute: What’s at Stake? The U.S. Department of Justice (DOJ) is siding with pharmaceutical giant AbbVie in a lawsuit against the state of Colorado, escalating a critical battle over the 340B Drug Pricing Program. This marks the first time the federal government has weighed in on the numerous … Read more